Origin Therapeutics Holdings (XCNQ:ORIG) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Origin Therapeutics Holdings's cash to debt ratio for the quarter that ended in Jun. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Origin Therapeutics Holdings could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Origin Therapeutics Holdings's Cash-to-Debt or its related term are showing as below:

XCNQ:ORIG' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 2 years, Origin Therapeutics Holdings's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

XCNQ:ORIG's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.92 vs XCNQ:ORIG: No Debt

Origin Therapeutics Holdings Cash-to-Debt Historical Data

The historical data trend for Origin Therapeutics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Origin Therapeutics Holdings Cash-to-Debt Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

Cash-to-Debt

No Debt

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial				No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Origin Therapeutics Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Cash-to-Debt falls into.

Origin Therapeutics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Origin Therapeutics Holdings's Cash to Debt Ratio for the fiscal year that ended in Sep. 2022 is calculated as:

Origin Therapeutics Holdings had no debt ⁽¹⁾.

Origin Therapeutics Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Origin Therapeutics Holdings had no debt ⁽¹⁾.

Origin Therapeutics Holdings (XCNQ:ORIG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Origin Therapeutics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.